Rigel Pharmaceuticals, Inc. Detailed Financials

Full historical quarterly statements

Metric	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	58.8M	69.8M	69.5M	101.7M	53.3M	57.6M	55.3M	36.8M
Cost of Goods Sold	4.6M	6.0M	4.8M	4.5M	4.4M	5.8M	8.0M	2.8M
Gross Profit	54.2M	63.8M	64.7M	97.2M	48.9M	51.8M	47.3M	34.0M
R&D Expenses	11.7M	10.7M	7.4M	6.8M	8.4M	5.6M	6.2M	5.5M
Operating Expenses	42.3M	40.7M	36.3M	36.1M	36.2M	35.2M	33.2M	33.6M
Operating Income	11.9M	23.2M	28.4M	61.1M	12.8M	16.7M	14.1M	447K
Other Income / Gains	-228K	-456K	-800K	-1.1M	-1.3M	-1.4M	-1.6M	-1.5M
Net Income	8.7M	268.1M	27.9M	59.6M	11.4M	14.3M	12.4M	-1.0M
EPS (Diluted)	0.47	14.72	1.55	3.33	0.64	0.81	0.71	-0.06
Reported Currency	USD	USD	USD	USD	USD	USD	USD	USD
Gross Profit Ratio	0.922	0.915	0.932	0.956	0.917	0.899	0.855	0.924
General And Administrative Expenses	0	0	0	0	0	0	0	0
Selling And Marketing Expenses	0	0	0	0	0	0	0	0
Selling General And Administrative Expenses	30.7M	30.0M	28.9M	29.3M	27.7M	29.5M	27.0M	28.0M
Other Expenses	0	0	0	0	0	0	0	0
Cost And Expenses	46.9M	46.6M	41.0M	40.6M	40.6M	40.9M	41.3M	36.4M
Interest Income	1.2M	1.2M	1.1M	753K	591K	522K	425K	552K
Interest Expense	1.4M	1.7M	1.9M	1.9M	1.9M	2.0M	2.1M	2.0M
Depreciation And Amortization	597K	601K	603K	607K	604K	604K	611K	613K
Ebitda	13.7M	25.0M	30.1M	62.5M	14.0M	17.8M	15.1M	1.6M
Ebitdaratio	0.233	0.358	0.434	0.614	0.262	0.309	0.273	0.044
Operating Income Ratio	0.202	0.332	0.409	0.601	0.239	0.289	0.254	0.012
Income Before Tax	11.7M	22.7M	27.6M	60.0M	11.5M	15.2M	12.4M	-1.0M
Income Before Tax Ratio	0.198	0.325	0.398	0.59	0.216	0.264	0.225	-0.028
Income Tax Expense	3.0M	-245.4M	-280K	369K	65K	881K	0	0
Net Income Ratio	0.147	3.84	0.402	0.586	0.215	0.249	0.225	-0.028
Epsdiluted	0.44	13.54	1.46	3.28	0.63	0.80	0.70	-0.06
Weighted Average Shs Out	18.4M	18.0M	18.0M	17.9M	17.8M	17.6M	17.6M	17.5M
Weighted Average Shs Out Dil	19.7M	18.8M	19.2M	18.2M	18.2M	18.0M	17.6M	17.5M